Treatment of HBV/HCV co-infected patients in DAA era
10.3969/j.issn.1001-5256.2017.06.001
- VernacularTitle:直接抗病毒药物时代HBV/HCV重叠感染的治疗
- Author:
Cheng WANG
;
Jiajie LIAO
- Keywords:
hepatitis B virus;
hepacivirus;
superinfection;
antiviral agents;
therapy;
editorial
- From:
Journal of Clinical Hepatology
2017;33(6):1011-1016
- CountryChina
- Language:Chinese
-
Abstract:
Asian-pacific area,especially China,is Hepatitis B high epidemic area.Since 2011,the first generation of oral direct anti-HCV agents (DAAs) came to clinical use,the treatment of chronic hepatitis C has switched from interferon-based regimen era to DAA era.There is an increased awareness of hepatitis B (HBV) reactivation in chronic hepatitis C (CHC) patients coinfected with HBV treated with pan-oral direct-acting antivirals(DAAs).Compared with interferon-based regimen,HBV reactivation occurred earlier and more severe among patients received DAA regimen,and even fetal cases or case end up with liver transplantation was reported.Thus,association of liver diseases called to alert the occurrence of HBV reactivation among CHC patients who received DAAs regimen.It is hence important to have HBV serology screened in all CHC patients before initiation of pan-oral DAAs therapy and the usefulness of preemptive administration of effective anti-HBV nucleos(t) ide analogues in coinfected patients need to be further studied.
